Key facts
- Notable investors include Vento, Compound (New York), Humba Ventures, R7.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Polyphron
- ·The full record, as it builds
Funding rounds
No funding rounds for Polyphron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Polyphron
Provider of cell therapeutic services intended to restore neural networks. The company offers to restore autonomy through spinal cord regeneration, recovering vision through optic nerve repair, and augmenting the central nervous system with replacement tissue, enabling the healthcare industry to engineer functional iPSC (induced pluripotent stem cells) derived tissue replacements.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 5
- Website
- polyphron.com/
- Ownership
- Privately Held (backing)
Polyphron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Polyphron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Polyphron in its N-PORT filings yet. We sweep new filings monthly.